Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Phase 2 Withdrawn Ohio State University Comprehensive Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

This study will determine the response rate of daily low dose interferon-alpha-2b in patients with metastatic or unresectable clear cell renal cell carcinoma.

Timeline

Start: —
Primary completion: —
Completion: 2006-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	interferon alfa-2b	Protein / enzyme biologic	—	Subcutaneous

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Summary

Timeline

Drugs

Indications